Gilead Sciences Strengthens Pipeline with Major Oncology Acquisition and HIV Progress

Gilead Sciences invests heavily in cell therapy with Arcellx acquisition while its core HIV business grows 6% to $20.8B, backed by positive Phase 3 trial data.

The biopharmaceutical giant Gilead Sciences is executing a significant strategic shift, channeling billions into expanding its oncology footprint while reinforcing its core HIV business. This dual approach, highlighted by a major acquisition and promising clinical data, is reshaping the company's future growth profile.

Financial Performance and HIV Segment Resilience

Gilead's financial foundation remains robust, driven substantially by its established HIV division. For the 2025 fiscal year, the company reported total revenue of approximately $29.4 billion. Within this figure, sales from its HIV portfolio grew by 6%, reaching $20.8 billion and continuing to serve as the firm's financial backbone.

Recent clinical developments promise to sustain this momentum. The company announced positive results from two Phase 3 trials for a novel HIV treatment combination involving Bictegravir and Lenacapavir. The data demonstrated that this regimen is equally effective at suppressing viral load compared to current standard therapies, potentially offering a new, effective option for patients.

A Strategic $7.8 Billion Move into Cell Therapy

In a decisive push to diversify its revenue sources, Gilead has agreed to acquire cancer specialist Arcellx for a total transaction value of nearly $7.8 billion. This acquisition is centered on gaining full control of a promising cell therapy for multiple myeloma.

Under the terms of the deal, Arcellx shareholders will receive $115 per share in cash. This price represents a substantial 68% premium over the stock's weighted average price during the preceding 30 trading days. Furthermore, a contingent value right offers an additional $5 per share, payable if the lead asset, anito-cel, achieves certain commercial milestones by the end of 2029.

The integration of Arcellx is anticipated to be finalized in the second quarter of 2026. All eyes are now on the U.S. Food and Drug Administration (FDA), which is expected to rule on the approval of anito-cel by the end of 2026. This regulatory decision stands as the next critical milestone for the therapy's commercial potential.

Market Reaction and Forward Focus

Investor sentiment appears favorable regarding Gilead's strategic direction. The company's shares have advanced close to 20% since the start of the year. Currently trading around €124, the stock sits roughly 5% below its 52-week high, which was recorded in mid-February.

Looking ahead, management's focus will be twofold: seamlessly integrating the Arcellx acquisition and navigating the regulatory pathway for its late-stage pipeline assets. The upcoming dialogue with health authorities will be crucial for bringing both the new HIV therapies and oncology candidates, like anito-cel, to market. The FDA's year-end decision on the cell therapy is poised to be a pivotal event for the company's growth trajectory in oncology.